Is TGTX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on BRIUMVI revenue growth and share gains, with revenue (ttm) at ~$800M; Q2 2026 ~$240M, up ~70% yoy. The bear case rests on the dominant risk is single-product concentration: with essentially all revenue from BRIUMVI, any slowdown in prescription growth, a pricing or reimbursement setback, or an unexpected safety signal would hit the whole company, unlike a diversified pharma. Analysts covering it are spread from $21.00 to $86.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is single-product concentration: with essentially all revenue from BRIUMVI, any slowdown in prescription growth, a pricing or reimbursement setback, or an unexpected safety signal would hit the whole company, unlike a diversified pharma. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $21.00, -61.1% from the $53.97 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

BRIUMVI revenue growth and share gains. The central driver is how fast BRIUMVI keeps growing. The most optimistic analyst target on TGTX is $86.00, +59.3% from the $53.97 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is single-product concentration: with essentially all revenue from BRIUMVI, any slowdown in prescription growth, a pricing or reimbursement setback, or an unexpected safety signal would hit the whole company, unlike a diversified pharma. The anti-CD20 MS market is crowded and competitive, with far larger and better-resourced rivals such as Roche's Ocrevus and Novartis's Kesimpta, plus the potential for new entrants and generics or biosimilars over time. Pipeline execution is another risk: the subcutaneous formulation and consolidated dosing programs still need to succeed in Phase 3 and win regulatory approval, and clinical trials can fail. As a mid-cap biotech, the stock is volatile and sensitive to quarterly sales prints, guidance changes, and clinical news, so drawdowns can be sharp even when the long-term story is intact. Earnings delivery is now a visible risk as well: EPS has missed consensus in each of the last four reported quarters, including $0.05 against $0.44 in the second quarter of 2026, and the balance sheet carries about $754 million of debt against about $552 million of cash. After an 85% gain in 2026, the share price also embeds higher expectations than it did at the start of the year. The most pessimistic published target is $21.00, -61.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (BRIUMVI revenue growth and share gains) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is single-product concentration: with essentially all revenue from BRIUMVI, any slowdown in prescription growth, a pricing or reimbursement setback, or an unexpected safety signal would hit the whole company, unlike a diversified pharma) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is BRIUMVI's rapid revenue growth, repeated guidance raises, and a recent swing to profitability, which helped lift the stock about 85% in 2026 through mid-October. The bear case is that nearly all revenue comes from one drug in a crowded MS market with much larger rivals, which makes the stock volatile and concentrated, and quarterly EPS has come in below estimates four times in a row. Weigh both against your own portfolio and consider consulting a licensed adviser.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on multiple sclerosis. Its business is built around one approved product, BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody for relapsing forms of MS that launched in the US in 2023. The company develops, markets, and sells this drug, and its pipeline mainly aims to extend BRIUMVI with new formulations and dosing schedules.

TGTX is a mid-cap biotech whose revenue comes almost entirely from a single drug, so its stock reacts sharply to each quarterly sales figure, guidance change, and clinical or competitive update. Single-product concentration means there is little to cushion any disappointment. Biotech stocks in general also carry regulatory and trial risk, which adds to price swings around news events.